Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CURX | 8-K | neutral | 4/10 | Curanex Pharmaceuticals disclosed two newly filed securities class actions related to its August 2025 IPO. Both lawsuits | Oct 19, 2026 |
| VVOS | PRESS-RELEASE | mixed | 6/10 | Vivos Therapeutics closed its acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in SOD' | Oct 19, 2026 |
| CYDY | DEFA14A | bullish | 6/10 | CytoDyn filed DEFA14A definitive additional proxy soliciting materials, which incorporate an 8-K announcing a CEO transi | Oct 19, 2026 |
| SUPN | 8-K | neutral | 2/10 | Supernus Pharmaceuticals filed an 8-K on October 19, 2026, solely to announce the date of its Q3 2026 earnings release a | Oct 19, 2026 |
| CYDY | 8-K | neutral | 5/10 | CytoDyn appointed CFO Robert E. Hoffman as CEO effective October 20, 2026, replacing Dr. Jacob Lalezari who transitions | Oct 19, 2026 |
| VVOS | 8-K | mixed | 6/10 | Vivos Therapeutics closed the acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in SOD' | Oct 19, 2026 |
| IRON | 144 | neutral | 3/10 | Atlas Venture Opportunity Fund I, L.P., a significant insider/affiliate of Disc Medicine (IRON), filed a Form 144 notice | Oct 19, 2026 |
| IRON | 144 | neutral | 2/10 | Atlas Venture Fund X, L.P., a major pre-IPO venture investor in Disc Medicine (IRON), filed a Form 144 on October 19, 20 | Oct 19, 2026 |
| IRON | 144 | neutral | 2/10 | Atlas Venture Fund XII, L.P., a major venture capital shareholder of Disc Medicine (IRON), filed a Form 144 on October 1 | Oct 19, 2026 |
| MLYS | 8-K | neutral | 2/10 | Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors, expanding the board from | Oct 19, 2026 |
| CRIS | 8-K | bearish | 6/10 | Curis entered into a securities purchase agreement to sell an aggregate of $8,500,006.80 of shares (or pre-funded warran | Oct 19, 2026 |
| SPRY | 144 | bearish | 5/10 | Eric Karas, an officer of ARS Pharmaceuticals, filed a Form 144 notice of intent to sell 100,000 shares of common stock, | Oct 19, 2026 |
| ELVN | 144 | neutral | 2/10 | Director Helen Collins filed a Form 144 notice of intent to sell 15,000 shares of Enliven Therapeutics (ELVN), with an e | Oct 19, 2026 |
| IBIO | 8-K | neutral | 3/10 | iBio, Inc. held its 2026 Annual Meeting on October 14, 2026, where stockholders approved an increase in authorized commo | Oct 19, 2026 |
| IRLA | 3 | neutral | 2/10 | Catherine M. Bonuccelli filed a Form 3 initial statement of beneficial ownership with IRulya Therapeutics Inc., indicati | Oct 19, 2026 |
| LTRN | DEF 14A | bearish | 6/10 | Lantern Pharma's 2026 definitive proxy statement schedules seven proposals for the December 1, 2026 annual meeting, incl | Oct 19, 2026 |
| IRLA | 3 | neutral | 2/10 | James Elwood Valentine filed an initial Statement of Beneficial Ownership (Form 3) with the SEC, reporting his status as | Oct 19, 2026 |
| CGON | 3 | neutral | 2/10 | Isabel Kalofonos filed a Form 3 initial statement of beneficial ownership with CG Oncology, Inc., reporting her position | Oct 19, 2026 |
| JAZZ | PRESS-RELEASE | neutral | 1/10 | Jazz Pharmaceuticals plc announced it will report its Q3 results on November 2, 2026. | Oct 19, 2026 |
| IRLA | 3 | neutral | 2/10 | John Drayton Wise filed a Form 3 initial statement of beneficial ownership with IRulya Therapeutics Inc., indicating he | Oct 19, 2026 |
| IRLA | 3 | neutral | 2/10 | Two Form 3 filings were submitted for IRulya Therapeutics Inc. by new officers John Militello (CFO) and Keith R. Fandric | Oct 19, 2026 |
| CRSP | 8-K | neutral | 3/10 | CRISPR Therapeutics announced the promotion of Andrew J. Silver from SVP, Finance to CFO, effective October 19, 2026, re | Oct 19, 2026 |
| SLN | DEFA14A | bullish | 7/10 | Silence Therapeutics announced a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany for $20.00 per AD | Oct 19, 2026 |
| IRLA | 3 | neutral | 1/10 | Leone D. Patterson filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting no securities ben | Oct 19, 2026 |
| VXRT | 8-K | neutral | 3/10 | Vaxart appointed retired Vice Admiral Raquel C. Bono, M.D., to its Board of Directors effective October 16, 2026, pursua | Oct 19, 2026 |
| TTRX | DEF 14A | neutral | 3/10 | Turn Therapeutics Inc. filed its definitive proxy statement for the 2026 annual meeting, seeking to re-elect CEO Bradley | Oct 19, 2026 |
| SCNX | 8-K | bullish | 6/10 | Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially from Q2 2026's ~$344K, driven b | Oct 19, 2026 |
| SLXN | DEFA14A | bearish | 6/10 | Silexion Therapeutics adjourned its extraordinary general meeting to October 26, 2026, without conducting business. The | Oct 19, 2026 |
| PMHS | 8-K | neutral | 3/10 | Two directors, Alexandra Peterson and Gabrielle Toledano, resigned from the board of Polomar Health Services, effective | Oct 19, 2026 |
| COLL | 8-K | mixed | 5/10 | Collegium Pharmaceutical settled its patent litigation with Grünenthal by paying $17 million to terminate the Grünenthal | Oct 19, 2026 |